Patents by Inventor Mark PETRONCZKI

Mark PETRONCZKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220133734
    Abstract: The present invention encompasses compounds of formula (I) wherein the groups R1 to R4 and X1 to X5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: October 29, 2021
    Publication date: May 5, 2022
    Inventors: Harald ENGELHARDT, Mark PETRONCZKI, Juergen RAMHARTER, Ulrich REISER, Heinz STADTMUELLER, Dirk SCHARN, Tobias WUNBERG
  • Patent number: 11174245
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: November 16, 2021
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Dietrich Boese, Georg Dahmann, Harald Engelhardt, Mark Petronczki, Dirk Scharn
  • Publication number: 20210332054
    Abstract: The present invention relates to new [1,3]diazino[5,4-d]pyrimidines and derivatives of Formula (I) wherein the groups R1, R2, R3 and R4 have the meanings given in the claims and specification, their use as inhibitors of HER2 and its mutants, pharmaceutical compositions which contain such compounds and their use as medicaments, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: April 6, 2021
    Publication date: October 28, 2021
    Inventors: Birgit WILDING, Dietrich BOESE, Harald ENGELHARDT, Julian FUCHS, Ralph NEUMUELLER, Mark PETRONCZKI, Dirk SCHARN, Matthias TREU
  • Publication number: 20200377476
    Abstract: The present invention encompasses compounds of formula (I) (I), wherein the groups R1 to R5 have the meanings given in the claims and specification, their use as inhibitors of mutant EGFR, pharmaceutical compositions which contain compounds of this kind and their use as medicaments/medical uses, especially as agents for treatment and/or prevention of oncological diseases.
    Type: Application
    Filed: February 20, 2019
    Publication date: December 3, 2020
    Inventors: Dietrich BOESE, Georg DAHMANN, Harald ENGELHARDT, Mark PETRONCZKI, Dirk SCHARN
  • Publication number: 20190125751
    Abstract: The invention describes anti-cancer therapies comprising using a 3G-EGFR inhibitor and an irreversible (2nd generation) EGFR TKI, each as described herein.
    Type: Application
    Filed: May 15, 2017
    Publication date: May 2, 2019
    Inventors: Flavio SOLCA, Mahmoud OULD KACI, Mark PETRONCZKI, Ulrike TONTSCH-GRUNT, Victoria ZAZULINA